DALLAS & LYON, France–(BUSINESS WIRE)–Regulatory News: SMAIO (Software, Machines and Adaptative Implants in Orthopaedics – Euronext Growth Paris, ISIN: FR0014005I80 / Ticker: ALSMA), a French-American player specialized in complex spine surgery with a global offer comprising software, adaptative implants and related services, today announced the appointment of Dr. Donald J. Blaskiewicz, neurosurgeon at St. Luke’s Clinic in Boise (Idaho) to its recently created U.S. scientific advisory board.
In mid-October 2024, SMAIO announced the creation of a U.S. scientific advisory board with the appointment of its two founding members, Dr. Brian Neuman (orthopedic surgeon) and Dr. Camilo Molina (neurosurgeon), both practicing at the Washington University School of Medicine in St. Louis (Missouri).
Today, the Company is glad to announce an important addition to the U.S. scientific advisory board with the appointment of Dr. Donald J. Blaskiewicz, neurosurgeon at St. Luke’s Clinic in Boise (Idaho).
Donald J. Blaskiewicz, MD, specializes in caring for people with complex spinal conditions, scoliosis, spinal deformity, and complex pathologies of the cervical spine. He is a fellow of the Scoliosis Research Society and the American Association of Neurological Surgeons (AANS). He is also a member of several professional organizations, including the Congress of Neurological Surgeons (CNS), the North American Spine Society (NASS), the Society of Minimally Invasive Surgery (SMISS) and the California Association of Neurological Surgeons (CANS).
SMAIO’s objective is to bring together the best experts in spine surgery within this advisory board in order to foster the Company’s development in the U.S. spine market, through various initiatives such as training sessions and the organization of “Sagittal Alignment Think Thanks” across North America.
Donald J. Blaskiewicz, neurosurgeon at St. Luke’s Clinic in Boise (Idaho),stated: “I look forward to discussing the company’s innovations with my fellow members of the Scientific Advisory Board, with the aim of significantly improving the care of patients requiring surgical realignment of the spine. I am convinced that SMAIO’s holistic approach to sagittal balance restoration will be of major interest to a growing number of surgeons wishing to provide their patients with the most personalized and optimized solutions.”
Philippe ROUSSOULY, Chairman and CEO of SMAIO,concluded: “I am pleased and honored to welcome Dr. Donald J. Blaskiewicz within our U.S. scientific advisory board. His in-depth knowledge of complex spine pathologies will be a major asset in high-level discussions with the other two members, Drs. Brian Neuman and Camilo Molina, who share the values and philosophy of SMAIO. Ranking among the most renowned experts in complex spine surgery in the U.S., their know-how will contribute significantly to the dissemination of our innovative technology to a growing number of surgeons, and ultimately patients, in the North American market, where we are already experiencing strong demand for our innovative solutions.”
The terms of remuneration of Dr. Donald J. Blaskiewicz as a member of the Scientific Advisory Board, mainly in the form of warrants issued to its benefit, are detailed in the appendix to this press release.
About SMAIO
A precursor in the use of clinical data and imaging of the spine, SMAIO designs global solutions for spine surgery specialists. The Company has recognized expertise thanks to KEOPS, its Big Data management software that has become a global reference with more than 100,000 patient cases documented.
SMAIO offers spine surgeons a comprehensive platform, I-Kontrol, incorporating planning, implants and related services, enabling them to treat spinal pathologies in a safe, effective and lasting way.
SMAIO is positioned at the forefront of innovation with the ambition of providing surgeons with the first active robotic solution enabling a high level of performance and repeatability to be achieved.
Based in Lyon, France, SMAIO benefits from the skill and expertise of more than 40 highly specialized staff.
For further information, please visit our website: www.smaio.com
Listing market: Euronext Growth Paris
ISIN: FR0014005I80
Ticker: ALSMA
Disclaimer
This press release contains non-factual elements, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could result in significant differences in results, profitability and expected events. In addition, SMAIO, its shareholders and its affiliates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical information or forecast information contained within this news release and that originates or is derived from third party sources or industry publications; these statistical data and forecast information are only used in this press release for information purposes. Finally, this press release may be drafted in French and in English. In the event of differences between the two texts, the French version will prevail.